Faculty of Medicine, Universidad Nacional de Colombia, Colombia.
Title: Imiquimod for anogenital warts in non-immunocompromised adults
Biography: Carlos Fernando
The imiquimod was superior to placebo in achieving complete and partial regression. When compared with placebo, the effects of imiquimod on recurrence, appearance of new warts and frequency of systemic adverse reactions were imprecise. Imiquimod led to more local adverse reactions and pain. Two trials compared imiquimod versus any other patient-applied treatment. The effects of imiquimod on complete regression, partial regression, recurrence or the presence of local adverse reactions were imprecise. Systemic adverse reactions were less frequent with imiquimod. Finally, two trials compared imiquimod with any other provider-administered treatment. The imiquimod did not have a lower frequency of complete regression. Imiquimod led to a lower rate of recurrence during six-month follow-up but this did not translate in to a lower recurrence from six to 12 months. The benefits and harms of imiquimod compared with placebo should be regarded with caution due to the risk of bias. The evidence for many of the outcomes that show imiquimod and patient-applied treatment confer similar benefits but fewer systematic reactions with the Imiquimod.